Data availability statement:
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
REFERENCES:
[1] LIEVERSE R I Y, VAN LIMBERGEN E J, OBERIJE C J G, et al. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial [J]. BMC Cancer, 2020, 20(1): 557.
[2] WANG Y, ZHANG T, HUANG Y, et al. Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis [J]. Int J Radiat Oncol Biol Phys, 2022, 112(5): 1154-64.
[3] WU M, LIU J, WU S, et al. Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer [J]. Front Immunol, 2021, 12(803247.
[4] CHEN J, WEI S, ZHAO T, et al. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB [J]. Dis Markers, 2022, 2022(7137357.
[5] NISHIO M, BARLESI F, WEST H, et al. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial [J]. J Thorac Oncol, 2021, 16(4): 653-64.
[6] GANDHI L, RODRIGUEZ-ABREU D, GADGEEL S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J]. N Engl J Med, 2018, 378(22): 2078-92.
[7] GOMEZ D R, BLUMENSCHEIN G R, LEE J J, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study [J]. The Lancet Oncology, 2016, 17(12): 1672-82.
[8] XU Y, LI H, FAN Y. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer [J]. Front Oncol, 2021, 11(642883.
[9] AL-HALABI H, SAYEGH K, DIGAMURTHY S R, et al. Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy [J]. J Thorac Oncol, 2015, 10(11): 1601-7.
[10] YOSHIDA T, YOH K, NIHO S, et al. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation [J]. Lung Cancer, 2015, 90(3): 477-83.
[11] IYENGAR P, WARDAK Z, GERBER D E, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial [J]. JAMA Oncol, 2018, 4(1): e173501.
[12] TANG Y, XIA B, XIE R, et al. Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI [J]. Lung Cancer, 2020, 140(65-70.
[13] TUMATI V, IYENGAR P. The current state of oligometastatic and oligoprogressive non-small cell lung cancer [J]. J Thorac Dis, 2018, 10(Suppl 21): S2537-S44.
[14] GOMEZ D R, TANG C, ZHANG J, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study [J]. J Clin Oncol, 2019, 37(18): 1558-65.
[15] SHANG S, LIU J, VERMA V, et al. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates [J]. Cancer Commun (Lond), 2021, 41(11): 1086-99.
[16] CHEN Y, GAO M, HUANG Z, et al. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges [J]. Journal of Hematology & Oncology, 2020, 13(1):
[17] TURGEON. G-A, SIVA. A W A A A B S S. Radiotherapy and immunotherapy: a synergistic effect
in cancer care [J]. Med J Aust, 2018,
[18] SEAN P PITRODA S J C, RALPH R WEICHSELBAUM. Integration of radiotherapy and immunotherapy for
treatment of oligometastases [J]. Lancet Oncol 2019,
[19] MONDINI M, LEVY A, MEZIANI L, et al. Radiotherapy-immunotherapy combinations - perspectives and challenges [J]. Mol Oncol, 2020, 14(7): 1529-37.
[20] YU W D, SUN G, LI J, et al. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy [J]. Cancer Lett, 2019, 452(66-70.
[21] ZENG J, SEE A P, PHALLEN J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas [J]. Int J Radiat Oncol Biol Phys, 2013, 86(2): 343-9.
[22] RODRIGUEZ-RUIZ M E, VANPOUILLE-BOX C, MELERO I, et al. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect [J]. Trends Immunol, 2018, 39(8): 644-55.
[23] MENG L, XU J, YE Y, et al. The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients [J]. Front Immunol, 2021, 12(723609.
[24] LIU Y, DONG Y, KONG L, et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors [J]. J Hematol Oncol, 2018, 11(1): 104.
[25] FORMENTI S C, DEMARIA S. Combining radiotherapy and cancer immunotherapy: a paradigm shift [J]. J Natl Cancer Inst, 2013, 105(4): 256-65.
[26] BERNSTEIN M B, KRISHNAN S, HODGE J W, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? [J]. Nat Rev Clin Oncol, 2016, 13(8): 516-24.
[27] KORDBACHEH T, HONEYCHURCH J, BLACKHALL F, et al. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms [J]. Ann Oncol, 2018, 29(2): 301-10.
[28] SATO H, OKONOGI N, NAKANO T. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment [J]. Int J Clin Oncol, 2020, 25(5): 801-9.
[29] CHEN C, LIU Y, CUI B. Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment [J]. Hum Vaccin Immunother, 2021, 17(6): 1555-67.
[30] PESCE S, GREPPI M, GROSSI F, et al. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells [J]. Front Immunol, 2019, 10(1242.
[31] DENG L, LIANG H, BURNETTE B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice [J]. J Clin Invest, 2014, 124(2): 687-95.
[32] QIAO Y, FU E. Advances in the Study of Tumor-associated Macrophages in Lung Cancer [J]. Zhongguo Fei Ai Za Zhi, 2022, 25(1): 34-9.
[33] XU F, WEI Y, TANG Z, et al. Tumorassociated macrophages in lung cancer: Friend or foe? (Review) [J]. Mol Med Rep, 2020, 22(5): 4107-15.
[34] DENARDO D G, RUFFELL B. Macrophages as regulators of tumour immunity and immunotherapy [J]. Nat Rev Immunol, 2019, 19(6): 369-82.
[35] DONLON N E, POWER R, HAYES C, et al. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity [J]. Cancer Lett, 2021, 502(84-96.
[36] WALTON E L. Radiotherapy and the tumor microenvironment: The ”macro” picture [J]. Biomed J, 2017, 40(4): 185-8.
[37] CAO L, CHE X, QIU X, et al. M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer [J]. Cancer Manag Res, 2019, 11(6125-38.
[38] LI W, WU F, ZHAO S, et al. Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy [J]. Cytokine Growth Factor Rev, 2022, 67(49-57.
[39] LIU Y, ZUGAZAGOITIA J, AHMED F S, et al. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy [J]. Clin Cancer Res, 2020, 26(4): 970-7.
[40] MILLS C D, LENZ L L, HARRIS R A. A Breakthrough: Macrophage-Directed Cancer Immunotherapy [J]. Cancer Res, 2016, 76(3): 513-6.
[41] GAO J, LIANG Y, WANG L. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy [J]. Frontiers in Immunology, 2022, 13(
[42] AMININ D, WANG Y M. Macrophages as a ”weapon” in anticancer cellular immunotherapy [J]. Kaohsiung J Med Sci, 2021, 37(9): 749-58.
[43] LI M, GAN L, SONG A, et al. Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy [J]. Biochim Biophys Acta Rev Cancer, 2019, 1871(2): 323-30.
[44] ARINA A, GUTIONTOV S I, WEICHSELBAUM R R. Radiotherapy and Immunotherapy for Cancer: From ”Systemic” to ”Multisite” [J]. Clin Cancer Res, 2020, 26(12): 2777-82.
[45] WEN L, TONG F, ZHANG R, et al. The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy [J]. Front Oncol, 2021, 11(799957.
[46] DOYEN J, BESSE B, TEXIER M, et al. PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial [J]. Clinical Lung Cancer, 2022, 23(3): e252-e6.
[47] CHEN D, BARSOUMIAN H B, YANG L, et al. SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer [J]. Cancer Immunol Res, 2020, 8(7): 883-94.
[48] WANG X, SCHOENHALS J E, LI A, et al. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy [J]. Cancer Res, 2017, 77(4): 839-50.
[49] VAN DEN HEUVEL M M, VERHEIJ M, BOSHUIZEN R, et al. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy [J]. J Transl Med, 2015, 13(32.
[50] YIN L, XUE J, LI R, et al. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer [J]. Int J Radiat Oncol Biol Phys, 2020, 108(1): 212-24.
[51] WANG Z, WEI L, LI J, et al. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer [J]. Transl Lung Cancer Res, 2021, 10(12): 4368-79.
[52] THEELEN W, PEULEN H M U, LALEZARI F, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial [J]. JAMA Oncol, 2019, 5(9): 1276-82.
[53] LI S, CHEN K, YANG M, et al. Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis [J]. Front Immunol, 2022, 13(991431.
[54] RATNAYAKE G, SHANKER M, ROBERTS K, et al. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer [J]. Asia Pac J Clin Oncol, 2020, 16(1): 56-62.
[55] MILANO M T, KATZ A W, ZHANG H, et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study [J]. Int J Radiat Oncol Biol Phys, 2012, 83(3): 878-86.
[56] TAUGNER J, KASMANN L, EZE C, et al. Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting [J]. Cancers (Basel), 2021, 13(7):
[57] HUI Z, MEN Y, HU C, et al. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial [J]. JAMA Oncol, 2021, 7(8): 1178-85.
[58] RUSTHOVEN K E, KAVANAGH B D, BURRI S H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases [J]. J Clin Oncol, 2009, 27(10): 1579-84.
[59] ZHANG H, WAN C, HUANG J, et al. In Vitro Radiobiological Advantages of Hypofractionation Compared with Conventional Fractionation: Early-Passage NSCLC Cells are Less Aggressive after Hypofractionation [J]. Radiat Res, 2018, 190(6): 584-95.
[60] WANG X, LU Y, QIN Z, et al. Stereotactic Body Radiotherapy and Conventional Radiotherapy Induce Cytoskeleton Extension and Enlargement of Cell Morphology in Non-Small Cell Lung Cancer [J]. Dose Response, 2021, 19(4): 15593258211064499.
[61] SCHAUE D, MCBRIDE W H. Opportunities and challenges of radiotherapy for treating cancer [J]. Nat Rev Clin Oncol, 2015, 12(9): 527-40.
[62] THARIAT J, HANNOUN-LEVI J M, SUN MYINT A, et al. Past, present, and future of radiotherapy for the benefit of patients [J]. Nat Rev Clin Oncol, 2013, 10(1): 52-60.
[63] DALY M E, MONJAZEB A M, KELLY K. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer [J]. J Thorac Oncol, 2015, 10(12): 1685-93.
[64] WELSH J, MENON H, CHEN D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial [J]. Journal for ImmunoTherapy of Cancer, 2020, 8(2):
[65] PETERS S, FELIP E, DAFNI U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial [J]. Lung Cancer, 2019, 133(83-7.
[66] SHAVERDIAN N, LISBERG A E, BORNAZYAN K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial [J]. The Lancet Oncology, 2017, 18(7): 895-903.
[67] HWANG W L, NIEMIERKO A, HWANG K L, et al. Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy [J]. JAMA Oncol, 2018, 4(2): 253-5.
[68] TIAN S, SWITCHENKO J M, BUCHWALD Z S, et al. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis [J]. Int J Radiat Oncol Biol Phys, 2020, 108(1): 304-13.
[69] LI B, JIANG C, PANG L, et al. Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review [J]. Front Immunol, 2021, 12(627197.
[70] SENAN S, OZGUROGLU M, DANIEL D, et al. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial [J]. ESMO Open, 2022, 7(2): 100410.
[71] BANG A, WILHITE T J, PIKE L R G, et al. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy [J]. Int J Radiat Oncol Biol Phys, 2017, 98(2): 344-51.
[72] VON REIBNITZ D, CHAFT J E, WU A J, et al. Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition [J]. Adv Radiat Oncol, 2018, 3(3): 391-8.